Zimmer Biomet Holdings, Inc.

{
  "main_header": {
    "sid": 1163133,
    "name": "Zimmer Biomet Holdings, Inc.",
    "stock_name": "Zimmer Biomet Holdings, Inc.",
    "full_name": "Zimmer Biomet Holdings, Inc.",
    "name_url": "stocks-analysis/zimmer-biomet-holdings-inc",
    "exchange": 1,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "86.60",
    "chg": -6.23,
    "chgp": "-6.71%",
    "dir": -1,
    "prev_price": "92.83",
    "mcapval": "17,152.61",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US98956P1021",
    "curr_date": "Jan 23",
    "curr_time": "",
    "bse_nse_vol": "1.07 M",
    "exc_status": "Active",
    "traded_date": "Jan 23, 2026",
    "traded_date_str": "2026 01 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zimmer-biomet-holdings-inc-1163133-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Zimmer Biomet Hits Day Low of $85.84 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zimmer-biomet-hits-day-low-of-8584-amid-price-pressure-3676126",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZimmerBiometHol_priceRelatedfactors_3676126.png",
        "date": "2025-11-06 16:11:40",
        "description": "Zimmer Biomet Holdings, Inc. has faced notable stock volatility, with significant declines over various time frames, including a year-to-date drop of 17.12%. Financial challenges are evident, including a 28.26% decrease in net profit and a high debt-equity ratio, although institutional ownership remains strong at 99.22%."
      },
      {
        "title": "Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zimmer-biomet-holdings-inc-overvalued-or-undervalued-3673379",
        "imagepath": "",
        "date": "2025-11-05 11:10:20",
        "description": "As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Agilent Technologies, Inc. has a P/E of 27.42, while GE Healthcare Technologies, Inc. stands out with a much lower P/E of 15.07, indicating that Zimmer Biomet is positioned competitively within its industry.\n\nDespite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -2.32% compared to the index's 16.30%. Over the past five years, the company has seen a decline of 22.03%, while the S&P 500 has gained 109.18%, further emphasizing the challenges the company faces in generating shareholder value...."
      },
      {
        "title": "Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zimmer-biomet-holdings-inc-overvalued-or-undervalued-3670576",
        "imagepath": "",
        "date": "2025-11-04 11:16:18",
        "description": "As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics, with a P/E ratio of 25, a Price to Book Value of 2.25, and an EV to EBITDA of 13.72. In comparison to peers, Edwards Lifesciences Corp. has a higher P/E of 31.17, while GE Healthcare Technologies, Inc. shows a more attractive valuation with an EV to EBITDA of 12.18.\n\nDespite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -5.44% compared to the S&P 500's 16.30%. This underperformance over multiple periods, including a 5-year return of -24.52% versus the S&P 500's 109.18%, suggests that while the stock is fairly valued, it may face challenges in regaining investor confidence...."
      },
      {
        "title": "Zimmer Biomet Holdings, Inc. Experiences Revision in Its Stock Evaluation Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zimmer-biomet-holdings-changes-valuation-grade-from-expensive-to-fair-amid-price-increase-3667147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZimmerBiometHol_valuationdot_3667147.png",
        "date": "2025-11-03 16:03:01",
        "description": "Zimmer Biomet Holdings, Inc. has recently adjusted its valuation, with a current P/E ratio of 25 and a price-to-book value of 2.25. The company has experienced a decline in return metrics over various periods, contrasting with the performance of the S&P 500 and its industry peers."
      },
      {
        "title": "Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zimmer-biomet-holdings-inc-overvalued-or-undervalued-3666141",
        "imagepath": "",
        "date": "2025-11-03 11:15:30",
        "description": "As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E ratio of 31.17, while GE Healthcare Technologies, Inc. shows a more attractive EV to EBITDA of 12.18.\n\nDespite the fair valuation, Zimmer Biomet has underperformed compared to the S&P 500, with a year-to-date return of -4.80% versus the S&P 500's 16.30%. This trend continues over longer periods, indicating potential challenges ahead...."
      },
      {
        "title": "Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zimmer-biomet-holdings-inc-overvalued-or-undervalued-3664274",
        "imagepath": "",
        "date": "2025-11-02 11:08:49",
        "description": "As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. \n\nIn comparison to peers, Edwards Lifesciences Corp. has a higher P/E ratio of 31.17, while Agilent Technologies, Inc. stands at a P/E of 27.42, indicating that Zimmer Biomet is relatively more attractively priced within its industry. Notably, the company's stock has underperformed against the S&P 500 over multiple periods, with a year-to-date return of -4.80% compared to the S&P 500's 16.30%, reinforcing the notion that it is fairly valued but may face challenges in generating positive returns in the near term...."
      }
    ],
    "total": 17,
    "sid": "1163133",
    "stock_news_url": "https://www.marketsmojo.com/news/zimmer-biomet-holdings-inc-1163133"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Zimmer Biomet Hits Day Low of $85.84 Amid Price Pressure

2025-11-06 16:11:40

Zimmer Biomet Holdings, Inc. has faced notable stock volatility, with significant declines over various time frames, including a year-to-date drop of 17.12%. Financial challenges are evident, including a 28.26% decrease in net profit and a high debt-equity ratio, although institutional ownership remains strong at 99.22%.

Read full news article

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

2025-11-05 11:10:20

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Agilent Technologies, Inc. has a P/E of 27.42, while GE Healthcare Technologies, Inc. stands out with a much lower P/E of 15.07, indicating that Zimmer Biomet is positioned competitively within its industry. Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -2.32% compared to the index's 16.30%. Over the past five years, the company has seen a decline of 22.03%, while the S&P 500 has gained 109.18%, further emphasizing the challenges the company faces in generating shareholder value....

Read full news article

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

2025-11-04 11:16:18

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics, with a P/E ratio of 25, a Price to Book Value of 2.25, and an EV to EBITDA of 13.72. In comparison to peers, Edwards Lifesciences Corp. has a higher P/E of 31.17, while GE Healthcare Technologies, Inc. shows a more attractive valuation with an EV to EBITDA of 12.18. Despite the fair valuation, Zimmer Biomet has underperformed relative to the S&P 500, with a year-to-date return of -5.44% compared to the S&P 500's 16.30%. This underperformance over multiple periods, including a 5-year return of -24.52% versus the S&P 500's 109.18%, suggests that while the stock is fairly valued, it may face challenges in regaining investor confidence....

Read full news article

Zimmer Biomet Holdings, Inc. Experiences Revision in Its Stock Evaluation Metrics

2025-11-03 16:03:01

Zimmer Biomet Holdings, Inc. has recently adjusted its valuation, with a current P/E ratio of 25 and a price-to-book value of 2.25. The company has experienced a decline in return metrics over various periods, contrasting with the performance of the S&P 500 and its industry peers.

Read full news article

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

2025-11-03 11:15:30

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E ratio of 31.17, while GE Healthcare Technologies, Inc. shows a more attractive EV to EBITDA of 12.18. Despite the fair valuation, Zimmer Biomet has underperformed compared to the S&P 500, with a year-to-date return of -4.80% versus the S&P 500's 16.30%. This trend continues over longer periods, indicating potential challenges ahead....

Read full news article

Is Zimmer Biomet Holdings, Inc. overvalued or undervalued?

2025-11-02 11:08:49

As of 31 October 2025, the valuation grade for Zimmer Biomet Holdings, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 25, an EV to EBITDA of 13.72, and a Price to Book Value of 2.25. In comparison to peers, Edwards Lifesciences Corp. has a higher P/E ratio of 31.17, while Agilent Technologies, Inc. stands at a P/E of 27.42, indicating that Zimmer Biomet is relatively more attractively priced within its industry. Notably, the company's stock has underperformed against the S&P 500 over multiple periods, with a year-to-date return of -4.80% compared to the S&P 500's 16.30%, reinforcing the notion that it is fairly valued but may face challenges in generating positive returns in the near term....

Read full news article

View All News